We evaluated the frequencies and clincopathologic significance of mutations in KRAS, BRAF, and PIK3CA, and HER2 amplification, as well as the relationship of these genetic alterations in advanced CRC patients who were candidates for anti-EGFR treatment in daily practice. The gene discussed is EGFR; the disease is colorectal carcinoma.